Amryt Research

Amryt Pharma is a global commercial-stage biopharmaceutical company dedicated to acquiring, developing, and commercializing innovative treatments for patients with rare and orphan diseases. The company's portfolio includes Filsuvez, the first approved treatment for partial thickness wounds associated with junctional and dystrophic epidermolysis bullosa, and Myalept, used for leptin deficiency in patients with generalized lipodystrophy. Amryt also markets Juxtapid for homozygous familial hypercholesterolemia and Mycapssa for acromegaly. In April 2023, the company was acquired by Chiesi Farmaceutici, integrating its rare disease expertise into Chiesi's global operations.